摘要
目的评价脂必泰联合非诺贝特对混合型高脂血症的疗效及安全性。方法选取68例混合型高脂血症患者,服用脂必泰及非诺贝特,随访2个月,观察治疗前后血浆总胆固醇(TC)、血浆三酰甘油(TG)及低密度脂蛋白(LDL-C)水平的变化,并监测血氨基转移酶及肌酸激酶的水平。结果脂必泰联合非诺贝特对混合型高脂血症患者治疗2个月后,TC从治疗前(6.11±0.67)mmol/L降至(4.02±0.51)mmol/L;TG从治疗前(4.32±2.20)mmol/L降至(1.88±0.72)mmol/L;LDL-C从治疗前(4.01±1.21)mmol/L降至(2.41±0.91)mmol/L;治疗期间,患者肌酸激酶、肌酐均无异常升高,1例患者氨基转移酶轻度升高。结论脂必泰联合非诺贝特对混合型高脂血症降脂效果明显,临床应用安全。
Objective To evaluate the clinical efficacy and safety of Chinese medicine Zhibitai combined fenofibrate in patients with mixed hyperlipidemia.Methods 68 patients with mixed hyperlipidemia took Zhibitai and fenofibrate.Two months later,the change of total cholesterol（TC）,total triglyceride（TG） and low-density lipoprotein（LDL-C） were observed,aminotransferase and creatine kinase were monitored.Results Zhibitai combined fenofibrate treatment in patients with mixed hyperlipidemia after two months,total cholesterol,total triglyceride and low density lipoprotein were significantly decreased.During treatment,patients′ creatine kinase were not significantly elevated.A patient′s aminotransferase elevated.Conclusion Zhibitai combined fenofibrate treatment in patients with mixed hyperlipidemia lipid-lowering effect is obvious and Clinical application is safe.
出处
《实用心脑肺血管病杂志》
2011年第4期614-615,共2页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
